Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients

被引:4
|
作者
Yang, Lin [1 ]
Yang, Nan [2 ]
Yi, Bin [1 ]
Pei, Qi [2 ]
Huang, Zhijun [1 ,3 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Nephrol, Changsha 410013, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha 410013, Peoples R China
[3] Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha 410013, Peoples R China
基金
中国国家自然科学基金;
关键词
External evaluation; Individualized drug administration; Population pharmacokinetics; Primary nephrotic syndrome; Tacrolimus; KIDNEY; CONCLUSIONS; MANAGEMENT;
D O I
10.1007/s11095-022-03273-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose The generalizability of numerous tacrolimus population pharmacokinetic (popPK) models constructed to promote optimal tacrolimus dosing in patients with primary nephrotic syndrome (PNS) is unclear. This study aimed to evaluate the predictive performance of published tacrolimus popPK models for PNS patients with an external data set. Methods We prospectively collected 223 concentrations from 50 Chinese adult patients with PNS who were undergoing tacrolimus treatment. Data on published tacrolimus popPK models for adults and children with PNS were extracted from the literature. Model predictability was evaluated with prediction-based and simulation-based diagnostics and Bayesian forecasting. Results In prediction-based evaluation, none of the 11 identified published popPK models of tacrolimus had met a predefined criteria of a mean prediction error <= +/- 20%, and the prediction error within +/- 30% of the identified models didn't exceed 50%. Simulation-based diagnostics also indicated unsatisfactory predictability. Bayesian forecasting demonstrated amelioration in the model predictability with the inclusion of 2-3 prior observations. Moreover, the predictive performance of nonlinear models was not better than that of one-compartment models. Conclusions The prediction of tacrolimus concentrations for patients with PNS remains challenging; published models are not applicable for extrapolation to other hospitals. Bayesian forecasting significantly improved model predictability and thereby helped to individualize tacrolimus dosing.
引用
收藏
页码:1907 / 1920
页数:14
相关论文
共 50 条
  • [31] Evaluation of Published Population Pharmacokinetic Models to Inform Tacrolimus Therapy in Adult Lung Transplant Recipients
    Kirubakaran, Ranita
    Singh, Rani M.
    Carland, Jane E.
    Day, Richard O.
    Stocker, Sophie L.
    THERAPEUTIC DRUG MONITORING, 2024, 46 (04) : 434 - 445
  • [32] Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction
    Huang, Qiongbo
    Lin, Xiaobin
    Wang, Yang
    Chen, Xiujuan
    Zheng, Wei
    Zhong, Xiaoli
    Shang, Dewei
    Huang, Min
    Gao, Xia
    Deng, Hui
    Li, Jiali
    Zeng, Fangling
    Mo, Xiaolan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients
    Qin, Yan
    Jiao, Zheng
    Ye, Yan-Rong
    Shen, Yun
    Chen, Zhe
    Chen, Yue-Ting
    Li, Xiao-Yu
    Lv, Qian-Zhou
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 35 : 347 - 353
  • [34] Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients
    Jalil, Mariam H. Abdel
    Hawwa, Ahmed F.
    McKiernan, Patrick J.
    Shields, Michael D.
    McElnay, James C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (01) : 130 - 140
  • [35] External evaluation of published population pharmacokinetic models of polymyxin B
    Ya-qian Li
    Kai-feng Chen
    Jun-jie Ding
    Hong-yi Tan
    Nan Yang
    Ya-qi Lin
    Cui-fang Wu
    Yue-liang Xie
    Guo-ping Yang
    Jing-Jing Liu
    Qi Pei
    European Journal of Clinical Pharmacology, 2021, 77 : 1909 - 1917
  • [36] External evaluation of published population pharmacokinetic models of polymyxin B
    Li, Ya-qian
    Chen, Kai-feng
    Ding, Jun-jie
    Tan, Hong-yi
    Yang, Nan
    Lin, Ya-qi
    Wu, Cui-fang
    Xie, Yue-liang
    Yang, Guo-ping
    Liu, Jing-Jing
    Pei, Qi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (12) : 1909 - 1917
  • [37] External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
    Yang, Nan
    Wang, Jing
    Xie, Yueliang
    Ding, Junjie
    Wu, Cuifang
    Liu, Jingjing
    Pei, Qi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [38] Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models
    Wang, Dongdong
    Lu, Jinmiao
    Li, Qin
    Li, Zhiping
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (05) : 4023 - 4031
  • [39] Population pharmacokinetics of cyclosporine A in Chinese patients with nephrotic syndrome in individualized drug administration
    Liu, Ya-ou
    Jia, Bo
    Chen, Chao-yang
    Zhou, Ying
    Cui, Yi-min
    Zhou, Fu-de
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (01) : 1 - 9
  • [40] Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus
    Zhang, Huan-Xi
    Sheng, Chang-Cheng
    Liu, Long-Shan
    Luo, Bi
    Fu, Qian
    Zhao, Qun
    Li, Jun
    Liu, Yan-Feng
    Deng, Rong-Hai
    Jiao, Zheng
    Wang, Chang-Xi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 746 - 761